• Nachrichtendetail
• 

13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	SANOFI SA INHABER EO 2	920657	Xetra	89,870	03.06.24 16:54:23	+0,090	+0,10%	89,850	89,910	88,320	89,780
	REGENERON PHARMAC.DL-,001	881535	Frankfurt	909,200	03.06.24 14:09:52	+10,800	+1,20%	914,800	920,200	900,200	898,400